Previous 10 | Next 10 |
While COVID-19 has driven recent quarterly beats, the Street seems to be overlooking the better long-term positioning of Hologic's diagnostics business post-COVID-19. The pandemic greatly accelerated Hologic's diagnostics system placements and the large majority of COVID-19 customers ...
Rising demand for advanced diagnostic devices for predicting the early development of diseases and getting accurate results within less time should drive the diagnostics and research industry’s growth. Given the rising investments in the industry, prominent players in this space, Therm...
Repligen has seen another few very strong years, as its capital allocation track record remains impressive. The company has furthermore benefited from the pandemic, as organic growth has been very strong as well. I like the long-term potential, and while shares have seen a recent ...
Akre Capital Management’s 13F portfolio value increased from $16.24B to $17.92B this quarter. They decreased SBA Communications and Dollar Tree during the quarter. The top three positions are American Tower, Mastercard, and Moody’s, and they add up to ~39% of the ent...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Danaher's (DHR -0.1%) recent underperformance is a reason to buy shares, according to UBS, who has added the stock to its list of Pricing Power Standouts. Through Friday's close, Danaher shares are down 12.6% year to date. The firm said that even though it expects inflation to moder...
Fisher’s 13F portfolio value increased from ~$161B to ~$179B in Q4 2021. Amazon, Netflix, Meta Platforms, and PayPal Holdings were increased while reducing Visa, Cisco Systems, Walt Disney, Intel, Wal-Mart, UnitedHealth, and Starbucks this quarter. The top three positions a...
Life sciences and diagnostics company Danaher (NYSE: DHR) is one of the big winners of the pandemic. Its life sciences solutions help medical bodies develop vaccines and therapies for COVID-19, and its diagnostic tests help detect it. The stock is up 77% since the start of 2020, and...
Danaher Reports Fourth Quarter And Full Year 2021 Results PR Newswire WASHINGTON , Jan. 27, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2021. All results in this release re...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...